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Background: B-cell non-Hodgkin lymphoma represents a diverse group of hematological malignancies, of which
follicular lymphoma (FL) is one of the most common subtypes. Family and epidemiological studies suggest an
important genetic role in the etiology of FL. In recent genome-wide association studies (GWAS) of FL, several
genetic susceptibility loci have been identified on chromosome 6p21.33 (rs6457327) and 6p21.32 (rs10484561,
rs2647012) in the human leukocyte antigen class I and class II regions. To identify new genetic variants and further
elucidate the genetic basis of FL, a meta-analysis was performed of the top 1000 SNPs associated with FL risk from
two GWAS in the US, Denmark and Sweden (592 cases, 1541 controls), with independent validation in 107 cases
and 681 controls.
Results: rs9275517 and rs3117222 in the HLA class II region were validated and inversely associated with FL risk
(rs9275517: OR = 0.63, 95% CI = 0.55-0.73, p = 4.03 × 10-11; rs3117222: OR = 0.66, 95% CI = 0.57-0.77, p = 1.45 × 10-7).
rs9275517, which is in high linkage disequilibrium with rs2647012 (r2 = 0.9), was no longer associated with FL after
conditioning on rs2647012. The rs3117222 association was independent of established FL SNPs, but not of the
HLA-DPB1*0301 allele. Using publicly available gene expression profiles with matching genotype information, we
found that rs3117222 also was significantly correlated with increased HLA-DPB1 expression.
Conclusions: By performing a meta-analysis of two GWAS of FL, we further validated the relevance of HLA-
DPB1*0301 as a protective allele in the pathogenesis of FL. Moreover, the protective rs3117222 A allele correlated
with increased levels of HLA-DPB1, suggesting a possible disease mechanism involving HLA-DPB1 expression
regulation. Our results add further support to the major role of HLA genetic variation in the pathogenesis of FL.
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Meta-analysisBackground
Follicular lymphoma (FL) is a B-cell neoplasm that
represents the second most common form of B-cell non-
Hodgkin lymphoma (NHL). An important role for inhe-
rited genetic susceptibility for FL has been supported by
recent genome-wide association studies (GWAS) where
three independent susceptibility alleles have been identified
in the HLA class I (rs6457327) [1] and class II (rs10484561,
rs2647012) regions [2,3]. Follow-up HLA sequencing stud-
ies revealed that rs10484561 is in complete linkage
disequilibrium (LD) with the DRB1*0101-DQA1*0101-* Correspondence: chrisfs@berkeley.edu
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reproduction in any medium, provided the orDQB1*0501 extended haplotype, and rs2647012 is highly
correlated with DRB1*15-DQA1*01-DQB1*06 [4]. An in-
dependent inverse association with FL risk also was
found for DPB1*0301 [4]. Because previous GWAS
only attempted to validate the top 40 variants asso-
ciated with FL [2,3], here we conducted a meta-analysis of
the top 1000 SNPs from existing GWAS data in 592 FL
cases and 1541 controls from Denmark/Sweden (SCALE)
and the San Francisco Bay Area (SF-NHL2) to identify
new genetic variants and further elucidate the genetic
basis of FL. Validation genotyping of associated SNPs
was conducted in 107 FL cases and 681 controls from
an independent NHL case–control study population
(SF-NHL1). The effect of validated SNP genotypes onLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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available microarray data.
Results and discussion
After excluding the SNPs previously tested for validation
in the two GWAS [2,3], 62 SNPs located in 20 in-
dependent loci were associated with FL at a p-value
threshold of 1×10−4 in the random-effects meta-analysis
(Additional file 1: Table S1). For each independent locus,
we selected the SNP with the lowest p-value and removed
markers in LD. Of the remaining SNPs, only those with
evidence of association from at least a secondary marker
in the GWAS were taken forward to validation. Among
the 11 independent SNPs selected for validation in the SF
NHL1 study, two SNPs, rs9275517 and rs3117222, located
on 6p21.32 in the HLA class II region, were validated in
this third independent population (rs9275517: OR = 0.58,
95% CI: 0.37-0.92, FDR-adjusted p-value = 2.29 × 10-3;
rs3117222: OR = 0.46, 95% CI: 0.29-0.73, FDR-adjusted
p-value = 2.83 × 10-3, Additional file 2: Table S2). In the
combined analysis of all three studies, rs9275517 (random-
effects p-value = 4.03 × 10-11; Pheterogeneity = 0.76, I
2 = 0%)
and rs3117222 (random-effects p-value = 1.45 × 10-7;
Pheterogeneity = 0.77, I
2 = 0%) were associated with FL at a
genome-wide significant level (i.e., P < 5.0 × 10−7;
Table 1, Additional file 3: Table S3).
To determine whether rs9275517 and rs3117222 are in-
dependently associated with FL risk, we adjusted our mo-
dels for the previously identified FL-risk loci, rs10484561,
rs2647012, and rs6457327 [1-3]. The results showed that
rs9275517 was no longer associated with FL after condi-
tioning on rs2647012 in any of the studies (p-valueSF =
0.31, p-valueSCALE = 0.63, Additional file 4: Table S4). Fur-
ther, rs9275517 and rs2647012 are in high LD (r2 = 0.9
in HapMap-CEU), also suggesting that the signal obser-
ved for rs9275517 is not independent of the previously
validated protective rs2647012 allele [3]. In contrast,
rs3117222 maintained independent statistical significance
when each SNP was fitted in the logistic regression model
(p < 0.02, Additional file 4: Table S4). Because rs3117222
maps 6 kb downstream of the HLA-DPB1 gene, we also
tested the independence of rs3117222 with HLA-DPB1
alleles including DPB1*0301, an allele inversely associa-
ted with FL based on HLA sequencing studies of the
SF-NHL2 study population [4]. Haplotype analysis in the
SF-NHL2 data showed a significant difference in the fre-
quencies of the HLA-DPB1*0301-rs3117222 haplotype in
cases versus controls (p-value = 9.00 × 10-4, Additional file
5: Table S5) and the LD analysis suggested that rs3117222
was in LD with HLA-DPB1*0301 (r2 = 0.24, D' = 0.96).
When DPB1*0301 was included in the model, rs3117222
was no longer associated with FL (p-value = 0.33), indica-
ting that although rs3117222 is independent of previous-
ly reported FL-associated SNPs, its influence on FL riskcannot be delineated from the protective HLA-DPB1*0301
allelic association. Nonetheless, through rs3117222, this
study provides the first validation of the HLA-DPB1 locus
as protective in the pathogenesis of FL in two additional
independent studies (SCALE and SF-NHL1).
To explore whether rs3117222 affects HLA-DPB1 gene
expression, we used two publicly available mRNA ex-
pression datasets from the MuTHER [5] and Gen Cord
[6] projects. We found a strong correlation between the
protective rs3117222 A allele and increased HLA-DPB1
expression in all lymphoblastoid cell lines in both data-
sets (Figures 1 and 2), indicating that enhanced HLA-
DPB1 expression may play a protective role in the etiology
of FL. This hypothesis is in line with previous studies
where reduced HLA class II expression on Hodgkin
Reed–Sternberg cells and diffuse large B-cell lymphoma
(DLBCL) tumor cells has been associated with poor sur-
vival for classical HL [7] and DLBCL [8], respectively.
Based on a recent HLA sequencing study of FL [4], we
showed that the protective versus deleterious HLA-DPB1
alleles possess oppositely charged glutamic acid rather
than lysine residues at position 69 in binding pocket 4,
factors that may influence peptide affinities for HLA-
DPB1 [9]. The present study suggests that an additional
mechanism involving effects on HLA-DPB1 expression
may also influence FL risk. Further studies will be needed
to confirm and clarify the specific mechanisms through
which reduced HLA-DPB1 expression may contribute
to deregulated cellular processes that drive FL and its
progression.
Conclusions
In the present study, we found that rs3117222 was in-
versely associated with FL risk independent of previously
published FL SNPs, but not independent of the HLA-
DPB1*0301 allele. Elevated levels of HLA-DPB1 trans-
cripts found in the presence of the protective rs3117222 A
allele suggest that changes in HLA-DPB1 expression may
be involved in the etiology of FL. These findings em-
phasize the important role of HLA genetic variation in FL
disease etiology and the need for further studies to clarify
the mechanisms through which HLA class II expression
contributes to FL pathogenesis.
Methods
Description of GWAS subjects, genotyping and statistical
analyses
SF-NHL2 GWAS
Full details of the study design and methods, genotyping,
quality control and statistical analyses have been described
elsewhere [2]. A total of 312,768 markers genotyped in
213 FL cases and 750 controls passed our quality control
criteria and were used for genome-wide association ana-
lysis. Population stratification and cryptic relatedness were




















































*P-values and ORs estimated from the meta-analysis were identical for the random- and fixed-effects models.



















Figure 1 Correlation of rs3117222 genotypes with HLA-DPB1 expression in the MuTHER dataset. Cell lines: F = adipose, L = lymphoblastoid,
S = skin.
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ting in a final inflation factor λ = 1.04. Associations with
FL were tested using a Cochran-Armitage trend test in
PLINK 1.07 [10]. Odd ratios (OR) and 95% confidence
intervals (95% CI) were calculated using the mid-p me-
thod from the epitools package in R [11].SCALE GWAS
Full details of the study design and methods, genotyping,
quality control and statistical analyses have been pub-
lished [3]. The final analysis included 298,680 genetic
variants available for 379 cases and 791 controls. Study
subjects with evidence of cryptic family relationships
or outliers in terms of population stratification were re-
moved as described previously [3], resulting in a final in-
flation factor λ = 1.028. Wald tests, treating minor allele
counts as continuous covariates were used to test for
association.Figure 2 Correlation of rs3117222 genotypes with HLA-DPB1 expressio
T = T-cell.Validation study (SF-NHL1)
Full details of this population-based San Francisco Bay
Area case–control study of NHL (1,591 cases, 2,515
controls) have been published [12,13]. Here, a subset of
HIV-negative, non-Hispanic white individuals (107 FL
cases, 681 controls) were used for validation.
The SF-NHL1 and SF-NHL2 study protocols were
approved by the UCSF ethics review committee (Nos.
10–03698 and 10–00629, respectively), and the SCALE
study was approved by the Ethical Review Board at
Karolinska Institutet, Stockholm, Sweden (Dnr 99–154,
2007/624-32). All study participants provided informed
consent.
Statistical analysis
Meta-analysis of the SF-NHL2 and SCALE GWAS
We selected for meta-analysis the top 1000 SNPs most
significantly associated with FL in the SF and SCALE
GWAS. Among these SNPs, 13 (rs9275572, rs10484561,n in the Gen Cord dataset. Cell lines: F = fibroblast, L = lymphoblastoid,
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rs2857106, rs2157051, rs12529049, rs10511017, rs587791
and rs3130617) were present in the top 1000 of both
GWAS. Selected SCALE GWAS SNPs that were not ge-
notyped or did not pass direct genotyping quality control
in the SF study were imputed using BEAGLE 3.0.3 [14]
with haplotype data from HapMap phase II-CEU as a
reference. Similarly, selected SF GWAS SNPs that were
not genotyped in the SCALE study were imputed from
the 1000 Genomes pilot1 CEU (August 2009 release) and
the HapMap Phase II release 22 CEU datasets using
IMPUTEv1 [15]. ORs for each individual study were es-
timated using unconditional logistic regression under an
additive model in PLINK. Before meta-analysis, genomic
control (GC) was applied to each study by multiplying the
standard error of the effect estimates by the square root of
the study-specific inflation factor (λ = 1.04 in SF, λ = 1.03
in SCALE). ORs and GC-corrected standard errors
were then combined in a meta-analysis under fixed- and
random-effects inverse variance models using the metagen
function from the meta package in R [16]. Heterogeneity
across studies was tested with the Cochran’s Q test and
quantified with the I2 heterogeneity index.
Validation - SNP selection and analysis
We selected for validation those SNPs with a random-
effects p-value threshold <10-4 in the meta-analysis. To
focus on newly associated loci not previously reported,
the top 40 SNPs associated with FL from each GWAS
were excluded from further validation, as these had been
tested previously [2,3]. For the remaining markers, we
used PLINK to group SNPs in LD based on genotypes
from HapMap-CEU r28, resulting in 20 independent loci
(r2 < 0.05). Eleven of these SNPs were taken forward to
the validation stage based on 1) lowest meta-analysis
p-value and 2) evidence of a secondary signal at each
locus in the original GWAS. Association analyses were
conducted using trend and logistic regression tests in
PLINK 1.07. P-values were adjusted for multiple com-
parisons using the Benjamini-Hochberg FDR correction
from the p-adjust function in R [17] and considered sig-
nificant at a FDR adjusted p-value level = 0.05. ORs and
95% CI were calculated for the variant allele carriers
using the epitools package. To estimate overall associa-
tion in the discovery and validation phases, logistic re-
gression ORs and standard errors for the validated SNPs
were combined with GC-corrected estimates from the
original GWAS in a meta-analysis under fixed- and
random-effects models.
Statistical analysis adjusting for previously associated
variants
Logistic regression analysis was conducted adjusting
for the additive effects of FL-associated SNPs that wereentered separately into the model as covariates using a
0,1,2 allele dosage coding. The same approach was used in
the SF-NHL2 dataset to test for independent effects
between SNPs and HLA alleles that were previously
typed in 205 FL cases and 82 controls as part of the SF
GWAS [4]. HLA alleles were coded as binary alleles where
A = present and B = absent.
Linkage disequilibrium (LD) and haplotype analysis
LD metrics between SNPs were based on European sam-
ples (CEU) from HapMap release 28 [18]. LD between
rs3117222 and HLA-DPB1 alleles were based on geno-
type and HLA typing data from the SF GWAS study.
Haplotype analyses were carried out with Haploview
[19].
Gene expression analysis
Associations with gene expression were investigated
using two publicly available datasets, one with 166 adi-
pose, 160 skin, and 156 lymphoblastoid cell lines derived
from a subset of healthy female twins of the MuTHER
study [5], and a second dataset with three cell types
(fibroblast, lymphoblastoid and T-cell) derived from um-
bilical cords of 75 Geneva GenCord individuals [6]. Cor-
relation between SNPs and gene expression levels was
assessed by the Spearman rank correlation test with
p-values adjusted by permutations using the Genevar
application [20].
Additional file
Additional file 1: Table S1. List of single-nucleotide polymorphisms
(SNPs) that were significantly (random effects p-value < 10-4) associated
with risk of follicular lymphoma (FL) in the meta-analysis of 592 FL cases
and 1541 controls from Denmark/Sweden (SCALE) and the San Francisco
Bay Area (SF-NHL2) studies. Table S2. Results for the 11 single-nucleotide
polymorphisms (SNPs) selected for validation in an independent follicular
lymphoma case–control study from the SF Bay Area (SF-NHL1). Table S3.
Meta-analysis of the combined GWAS and validation datasets for the 11
SNPs selected for validation. Table S4. Logistic regression results for the
validated SNPs in the SF-NHL2 and SCALE GWAS. P-values were
computed in a logistic regression model with and without adjustment
for established FL-associated SNPs. Table S5. Case–control frequencies
and association p-values for the most frequent HLA-DPB1/rs3117222
haplotypes in the SF-NHL2 population.
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